Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease (PERSEUS)

Okayama University34 enrolled

Overview

The purpose of this study is to investigate the efficacy of intracoronary infusion of cardiac progenitor cells in patients with univentricular heart disease. Patients with preoperative high-risk group or whose cardiac function did not recover postoperatively eventually have no choice other than heart transplantation.

Following the safety verification of the Phase I study (TICAP trial) that has been implemented and completed, the efficacy will be verified in this Phase II clinical study. The rationale of this study is based on the animal studies that transplanted cardiac progenitor cells may regenerate damaged myocardium by giving rise to cardiac muscle and vascular cell types. Preclinical and phase I studies indicate the possibilities of cardiac function improvements and reduced myocardial fibrosis by progenitor cell infusion. The efficacy of cell transplantation is assessed as the primary endpoint of the Phase II clinical study. The improvements of cardiac ejection fraction assessed by echocardiography, ventriculography, and cardiac MRI, which are conducted before and after treatment, are assessed as the evaluation items. The absolute values of the improvement of cardiac ejection fraction obtained by the above three imaging modalities before and after treatment are compared between two groups of the transplantation group and non-transplantation group.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hypoplastic Left Heart Syndrome Single Right Ventricle Single Left Ventricle

Interventions

Cardiac progenitor cell infusionGENETIC

(Stage 1) Cardiac progenitor cell infusion in patients who assigned as active comparator group (Stage 2) Rescuing transplantation is applicable in patients, along with their written consent, 4 months after palliations who were allocated as control group in stage 1.

Eligibility

Sex: ALLMax age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age: Age is 0 year or more and 20 years or less at the time of enrollment. 2. The patients have functional single ventricular physiology with the indication to have stage-2 or -3 palliative surgeries. 3. The ventricular ejection fraction \<60%. Exclusion Criteria: 1. Cardiogenic shock 2. A patient with unstoppable extracorporeal circulation 3. A patient with lethal, uncontrollable arrhythmia 4. A patient with a complication of coronary artery disease 5. A patient with a complication of brain dysfunction due to circulatory failure 6. A patient with malignant neoplasm 7. A patient with a complication of serious neurologic disorder 8. A patient with high-grade pulmonary embolism or pulmonary hypertension 9. A patient with high-grade renal failure 10. A patient with multiple organ failure 11. Active infection (including endocarditis) 12. Sepsis 13. Active hemorrhagic disease (e. g. gastrointestinal bleeding, injury)

Locations (1)

Okayama University

Okayama, Japan

Outcomes

Primary Outcomes

Cardiac function

The primary outcome measure is to evaluate the cardiac function improvement by echocardiography, ventriculography, and cardiac MRI, which are conducted before and 3 months after surgical treatment.

Time frame: 3 Months

Secondary Outcomes

Cardiac function

The secondary outcome measure is to determine the cardiac function improvements by three different imaging modalities at 12 months after treatment.

Time frame: 12 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.